Literature DB >> 34396402

Using Innovation to Address Adolescent and Young Adult Health Disparities in Pelvic Inflammatory Disease: Design of the Technology Enhanced Community Health Precision Nursing (TECH-PN) Trial.

Maria Trent1, Jamie Perin1, Julia Rowell1, Maunank Shah2, Jennifer Anders1, Pamela Matson1, Rebecca M Brotman3, Jacques Ravel3, Phyllis Sharps4, Richard Rothman5, Hasiya E Yusuf1, Charlotte A Gaydos2.   

Abstract

New approaches to pelvic inflammatory disease (PID) care among adolescents and young adults (AYAs) that optimize self-care and personalize treatment are warranted to address age and racial-ethnic PID-related health disparities. Here we describe the 13-month preliminary feasibility and acceptability outcomes of recruitment, retention, and intervention delivery for Technology Enhanced Community Health Precision Nursing (TECH-PN) randomized controlled trial. Urban AYAs 13-25 years assigned female sex at birth with acute mild-moderate PID provided baseline and follow-up interview data and vaginal specimens for sexually transmitted infection (STI), cytokine, and microbiota assessment. All participants received medications and text-messaging support. Participants were block randomized to either control or intervention. Control participants received 1 community nursing visit with self-management for interim care per national guidelines. Intervention participants received unlimited precision care services driven by interim STI and macrolide resistance testing results by an advanced practice provider. In the first 13 months, 75.2% patients were eligible, and 76.1% of eligible patients enrolled. Of the participants, 94% completed the intervention and 96%, 91%, and 89%, respectively, completed their 14-, 30-, and 90-day visits. Baseline laboratory results revealed infection rates that were highest for Mycoplasma genitalium (45%) followed by Chlamydia trachomatis (31%). Preliminary enrollment, STI, intervention delivery, and retention data demonstrate the feasibility and acceptability of the TECH-PN intervention and support rationale for precision care for PID among urban AYAs. ClinicalTrials.gov Identifier. NCT03828994.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Chlamydia trachomatiszzm321990 ; zzm321990 Mycoplasma genitaliumzzm321990 ; zzm321990 Neisseria gonorrhoeaezzm321990 ; zzm321990 Trichomonas vaginaliszzm321990 ; Pelvic Inflammatory Disease (PID); adolescents and young adults (AYAs); clinical trial; disparities; genomic; precision-nursing; sexually transmitted infections

Mesh:

Substances:

Year:  2021        PMID: 34396402      PMCID: PMC8365117          DOI: 10.1093/infdis/jiab157

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  40 in total

1.  Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.

Authors:  Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

2.  Hospitalization for pelvic inflammatory disease: a cost-effectiveness analysis.

Authors:  Kenneth J Smith; Roberta B Ness; Mark S Roberts
Journal:  Sex Transm Dis       Date:  2007-02       Impact factor: 2.830

3.  Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study.

Authors:  Maria Trent; Debra Bass; Roberta B Ness; Catherine Haggerty
Journal:  Sex Transm Dis       Date:  2011-09       Impact factor: 2.830

4.  Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection.

Authors:  Lindi Masson; Kelly B Arnold; Francesca Little; Koleka Mlisana; David A Lewis; Nonhlanhla Mkhize; Hoyam Gamieldien; Sinaye Ngcapu; Leigh Johnson; Douglas A Lauffenburger; Quarraisha Abdool Karim; Salim S Abdool Karim; Jo-Ann S Passmore
Journal:  Sex Transm Infect       Date:  2015-10-28       Impact factor: 3.519

Review 5.  Status of adolescent pelvic inflammatory disease management in the United States.

Authors:  Maria Trent
Journal:  Curr Opin Obstet Gynecol       Date:  2013-10       Impact factor: 1.927

6.  Use of an institutional intervention to improve quality of care for adolescents treated in pediatric ambulatory settings for pelvic inflammatory disease.

Authors:  Maria Trent; Stephanie L Judy; Jonathan M Ellen; Allen Walker
Journal:  J Adolesc Health       Date:  2006-07       Impact factor: 5.012

7.  Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth.

Authors:  Anjani Chandra; Gladys M Martinez; William D Mosher; Joyce C Abma; Jo Jones
Journal:  Vital Health Stat 23       Date:  2005-12

8.  Recruitment of Minority Adolescents and Young Adults into Randomised Clinical Trials: Testing the Design of the Technology Enhanced Community Health Nursing (TECH-N) Pelvic Inflammatory Disease Trial.

Authors:  Maria Trent; Shang-En Chung; Charlotte Gaydos; Kevin D Frick; Jennifer Anders; Steven Huettner; Richard Rothman; Arlene Butz
Journal:  Eur Med J Reprod Health       Date:  2016-08

9.  Results of a randomized controlled trial of a brief behavioral intervention for pelvic inflammatory disease in adolescents.

Authors:  Maria Trent; Shang-en Chung; Michael Burke; Allen Walker; Jonathan M Ellen
Journal:  J Pediatr Adolesc Gynecol       Date:  2009-09-03       Impact factor: 1.814

10.  Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.

Authors:  L Weström; R Joesoef; G Reynolds; A Hagdu; S E Thompson
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

View more
  1 in total

1.  Clinical Efficacy Analysis of Fast Rehabilitation Nursing on Pain Mitigation after Lumbar Discectomy and Bone Graft Fusion and Internal Fixation.

Authors:  Lingling Fang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-09       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.